|
|
 |
|
Total Number of Holdings (excluding cash): 49
| Globus Medical, Inc. (Class A) |
GMED |
379577208 |
752 |
$71,101.60 |
3.57% |
| Align Technology, Inc. |
ALGN |
016255101 |
338 |
$63,047.14 |
3.17% |
| Hoya Corporation |
7741.JP |
J22848105 |
294 |
$55,641.35 |
2.80% |
| Penumbra, Inc. |
PEN |
70975L107 |
163 |
$54,184.46 |
2.72% |
| Masimo Corporation |
MASI |
574795100 |
294 |
$52,446.66 |
2.63% |
| Waters Corporation |
WAT |
941848103 |
159 |
$51,865.80 |
2.61% |
| WuXi AppTec Co., Ltd. (Class H) |
2359.HK |
Y971B1118 |
2,985 |
$49,901.97 |
2.51% |
| Alcon Inc. |
ALC.SW |
H01301128 |
589 |
$47,640.34 |
2.39% |
| Fisher & Paykel Healthcare Corporation Limited |
FPH.NZ |
Q38992105 |
2,046 |
$46,572.71 |
2.34% |
| Intuitive Surgical, Inc. |
ISRG |
46120E602 |
99 |
$46,367.64 |
2.33% |
| Koninklijke Philips N.V. |
PHIA.NA |
N7637U112 |
1,550 |
$45,156.38 |
2.27% |
| Edwards Lifesciences Corporation |
EW |
28176E108 |
576 |
$45,043.20 |
2.26% |
| Teleflex Incorporated |
TFX |
879369106 |
356 |
$44,977.04 |
2.26% |
| Revvity, Inc. |
RVTY |
714046109 |
482 |
$44,777.80 |
2.25% |
| Straumann Holding AG (Registered) |
STMN.SW |
H8300N127 |
393 |
$44,852.58 |
2.25% |
| GE HealthCare Technologies Inc. |
GEHC |
36266G107 |
599 |
$44,032.49 |
2.21% |
| The Cooper Companies, Inc. |
COO |
216648501 |
622 |
$43,720.38 |
2.20% |
| Mettler-Toledo International Inc. |
MTD |
592688105 |
33 |
$43,423.05 |
2.18% |
| West Pharmaceutical Services, Inc. |
WST |
955306105 |
163 |
$43,439.50 |
2.18% |
| Thermo Fisher Scientific Inc. |
TMO |
883556102 |
81 |
$43,065.27 |
2.16% |
| Bio-Rad Laboratories, Inc. (Class A) |
BIO |
090572207 |
143 |
$42,322.28 |
2.13% |
| Sartorius Stedim Biotech |
DIM.FP |
F8005V210 |
196 |
$42,407.44 |
2.13% |
| Zimmer Biomet Holdings, Inc. |
ZBH |
98956P102 |
449 |
$42,295.80 |
2.12% |
| Danaher Corporation |
DHR |
235851102 |
210 |
$41,609.40 |
2.09% |
| Smith & Nephew Plc |
SN/.LN |
G82343164 |
2,415 |
$41,289.90 |
2.07% |
| Demant A/S |
DEMANT.DC |
K3008M105 |
1,205 |
$40,596.19 |
2.04% |
| DexCom, Inc. |
DXCM |
252131107 |
654 |
$40,247.16 |
2.02% |
| Stryker Corporation |
SYK |
863667101 |
117 |
$39,925.08 |
2.01% |
| Steris Plc |
STE |
G8473T100 |
180 |
$39,870.00 |
2.00% |
| Medtronic Plc |
MDT |
G5960L103 |
446 |
$38,846.60 |
1.95% |
| Merit Medical Systems, Inc. |
MMSI |
589889104 |
539 |
$38,123.47 |
1.92% |
| Sonova Holding AG (Registered) |
SOON.SW |
H8024W106 |
157 |
$37,659.99 |
1.89% |
| Agilent Technologies, Inc. |
A |
00846U101 |
312 |
$37,368.24 |
1.88% |
| Olympus Corporation |
7733.JP |
J61240107 |
3,540 |
$35,941.27 |
1.81% |
| ResMed Inc. |
RMD |
761152107 |
156 |
$35,692.80 |
1.79% |
| Becton, Dickinson and Company |
BDX |
075887109 |
228 |
$35,458.56 |
1.78% |
| Siemens Healthineers AG |
SHL.GY |
D6T479107 |
778 |
$35,160.20 |
1.77% |
| Terumo Corporation |
4543.JP |
J83173104 |
2,560 |
$35,206.62 |
1.77% |
| BioMerieux |
BIM.FP |
F1149Y232 |
320 |
$34,809.52 |
1.75% |
| Baxter International Inc. |
BAX |
071813109 |
1,939 |
$34,126.40 |
1.71% |
| Coloplast A/S (Class B) |
COLOB.DC |
K16018192 |
485 |
$33,223.04 |
1.67% |
| Abbott Laboratories |
ABT |
002824100 |
321 |
$32,600.76 |
1.64% |
| Sysmex Corporation |
6869.JP |
J7864H102 |
3,434 |
$30,798.31 |
1.55% |
| Boston Scientific Corporation |
BSX |
101137107 |
446 |
$28,816.06 |
1.45% |
| Cochlear Limited |
COH.AU |
Q25953102 |
229 |
$28,260.45 |
1.42% |
| Carl Zeiss Meditec AG (Bearer) |
AFX.GY |
D14895102 |
860 |
$27,700.74 |
1.39% |
| Amplifon SpA |
AMP.IM |
T0388E118 |
2,487 |
$27,519.07 |
1.38% |
| Insulet Corporation |
PODD |
45784P101 |
135 |
$27,337.50 |
1.37% |
| US Dollar |
$USD |
|
3,951 |
$3,950.98 |
0.20% |
| Euro |
$EUR |
|
0 |
$0.06 |
0.00% |
| Pound Sterling |
$GBP |
|
0 |
$0.15 |
0.00% |
| TPG Inc. (CVR) |
2602335D |
436CVR021 |
612 |
$0.00 |
0.00% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|